[2]
Dhillon S. Aducanumab: First Approval. Drugs. 2021 Aug:81(12):1437-1443. doi: 10.1007/s40265-021-01569-z. Epub
[PubMed PMID: 34324167]
[3]
Cummings J, Salloway S. Aducanumab: Appropriate use recommendations. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022 Mar:18(3):531-533. doi: 10.1002/alz.12444. Epub 2021 Jul 27
[PubMed PMID: 34314093]
[4]
Walsh S, Merrick R, Milne R, Brayne C. Aducanumab for Alzheimer's disease? BMJ (Clinical research ed.). 2021 Jul 5:374():n1682. doi: 10.1136/bmj.n1682. Epub 2021 Jul 5
[PubMed PMID: 34226181]
[5]
Mahase E. Three FDA advisory panel members resign over approval of Alzheimer's drug. BMJ (Clinical research ed.). 2021 Jun 11:373():n1503. doi: 10.1136/bmj.n1503. Epub 2021 Jun 11
[PubMed PMID: 34117086]
[7]
Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2016 Apr:12(4):459-509
[PubMed PMID: 27570871]
[8]
Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, Sondhi D, Sullivan PM, Holtzman DM, Crystal RG, Paul SM. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of aging. 2016 Aug:44():159-172. doi: 10.1016/j.neurobiolaging.2016.04.020. Epub 2016 Apr 30
[PubMed PMID: 27318144]
[9]
Liu W, Zhao L, Blackman B, Parmar M, Wong MY, Woo T, Yu F, Chiuchiolo MJ, Sondhi D, Kaminsky SM, Crystal RG, Paul SM. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016 Dec 7:36(49):12425-12435
[PubMed PMID: 27927959]
[10]
Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. Journal of Alzheimer's disease : JAD. 2010:19(1):311-23. doi: 10.3233/JAD-2010-1221. Epub
[PubMed PMID: 20061647]
[11]
Vaz M, Silvestre S. Alzheimer's disease: Recent treatment strategies. European journal of pharmacology. 2020 Nov 15:887():173554. doi: 10.1016/j.ejphar.2020.173554. Epub 2020 Sep 15
[PubMed PMID: 32941929]
[12]
Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2021 Apr:17(4):696-701. doi: 10.1002/alz.12213. Epub 2020 Nov 1
[PubMed PMID: 33135381]
[13]
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1:537(7618):50-6. doi: 10.1038/nature19323. Epub
[PubMed PMID: 27582220]
Level 2 (mid-level) evidence
[14]
Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K, Bacskai BJ. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2016 Dec 14:36(50):12549-12558
[PubMed PMID: 27810931]
Level 2 (mid-level) evidence
[15]
Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussière T, Hamann S, Cameron TO, Weinreb PH. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Scientific reports. 2018 Apr 23:8(1):6412. doi: 10.1038/s41598-018-24501-0. Epub 2018 Apr 23
[PubMed PMID: 29686315]
Level 2 (mid-level) evidence
[16]
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2017 Jun 21:546(7659):564. doi: 10.1038/nature22809. Epub
[PubMed PMID: 28640269]
Level 2 (mid-level) evidence
[17]
Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer's research & therapy. 2021 May 10:13(1):98. doi: 10.1186/s13195-021-00838-z. Epub 2021 May 10
[PubMed PMID: 33971962]
[18]
Schneider L. A resurrection of aducanumab for Alzheimer's disease. The Lancet. Neurology. 2020 Feb:19(2):111-112. doi: 10.1016/S1474-4422(19)30480-6. Epub 2019 Dec 4
[PubMed PMID: 31978357]
[19]
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA neurology. 2022 Jan 1:79(1):13-21. doi: 10.1001/jamaneurol.2021.4161. Epub
[PubMed PMID: 34807243]
[20]
Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O'Gorman J, Sevigny J. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2016 Sep:2(3):169-176. doi: 10.1016/j.trci.2016.06.002. Epub 2016 Jun 20
[PubMed PMID: 29067304]
Level 1 (high-level) evidence
[21]
Mukhopadhyay S, Banerjee D. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2021:83(4):1537-1552. doi: 10.3233/JAD-215065. Epub
[PubMed PMID: 34366359]
[22]
Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2023 Jan:20(1):195-206. doi: 10.1007/s13311-022-01308-6. Epub 2022 Oct 17
[PubMed PMID: 36253511]